AGT is a gene and cell therapy company with a proprietary gene-delivery platform to rapidly develop cures to infectious diseases, cancers, and monogenic disorders. AGT’s mission is to transform people’s lives through genetic medicines that rid the body of disease. Its lead candidate for an HIV cure is expected to enter the clinic in 2019. In parallel, AGT has a patented immuno-oncology approach to stimulate the body’s immune system to destroy cancer. AGT has also developed a synthetic gene to cure Phenylketonuria (PKU). This treatment received an FDA Orphan Drug Designation and it’s expected to reach the clinic in 2020.